Sign in Create account

Bacil Pharma Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524516
₹26.07
▼ -0.06 (-0.23%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
41/100
Moderate
Valuation
45/100
Fairly Valued
Momentum
89/100
Bullish

QVM read Momentum-led Quality Moderate, Valuation Fairly Valued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹37 Cr
PE (TTM)
37.2
Industry median 36.1 (152 companies)
Price to Book
1.5
PEG (TTM)
-1.0
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-55.7
Free Cash Flow
₹2 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-54.17%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
6.91%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
0.00%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
162.90%
as of Dec. 31, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
12.61%
as of March 31, 2013
Industry median 14.05% (173 companies)
Current Ratio
0.68
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
Data unavailable.
Net Margin
-11.39%
as of March 31, 2013
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
Data unavailable.
Operating Margin (TTM)
9.72%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
4.13%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
3.99%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
4.55%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • No Return on equity is 15% or more (4.6%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

3 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.2%
Low 24.8300 · High 27.4300
1W return
8.9%
Low 24.2000 · High 28.7500
1M return
106.9%
Low 12.2500 · High 28.7500
52W return
-55.7%
Low 10.6500 · High 28.7500
Lifetime High ₹58.8900 (Dec. 24, 2024)
Lifetime Low ₹0.9600 (Dec. 16, 2013)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
25.8
10D
24.3
20D
21.9
50D
20.0
100D
18.6
200D
14.5

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
86.8%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

26.11
Pivot
First resistance27.39
Second resistance28.71
Third resistance29.99
First support24.79
Second support23.51
Third support22.19
Day RSI67.7
Day MFI82.9
Day MACD2.63
Day MACD signal1.89

Beta

1M-0.55
3M-0.01
1Y-0.01
3Y-0.36

Price change analysis

↑ 106.9%
Over 1 Month
LowHigh
12.2528.75
↓ -55.7%
Over 3 Months
LowHigh
10.6528.75
↓ -55.7%
Over 6 Months
LowHigh
10.6528.75
↓ -55.7%
Over 1 Year
LowHigh
10.6528.75
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 37.2 (own history: 30.8–140.2)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹0 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹0.2200

Ranks #158 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Dec 2025
  • Promoter0.08%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 0.08% in Dec 2025 qtr

All shareholding details →

Deals (Bulk & Block)

All 145 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
30 Sep 2026 SHRYNAX TRADING PRIVATE LIMITED Bulk Buy 136,317 25.5000 BSE
28 Aug 2026 BRENLEY ENGINEERS PRIVATE LIMITED Bulk Buy 84,658 11.6700 BSE
20 Aug 2026 VISHAL MAHESH WAGHELA Bulk Sell 80,000 11.7100 BSE
19 Aug 2026 MNM STOCK BROKING PVT. LTD. Bulk Buy 37,916 12.4400 BSE
19 Aug 2026 RAJESH HIRANI Bulk Buy 70,000 11.2800 BSE
19 Aug 2026 PRASHANT GUPTA Bulk Buy 82,000 11.3000 BSE
19 Aug 2026 PRASHANT GUPTA Bulk Sell 82,000 11.6200 BSE
19 Aug 2026 UTTAMCHANDANI SANDIP M Bulk Sell 87,757 11.3900 BSE
19 Aug 2026 YOGESH KIRTIBHAI PAREKH Bulk Buy 100,000 11.2600 BSE
19 Aug 2026 SPEXTRA MULTIBIZ PRIVATE LIMITED Bulk Sell 101,129 11.3100 BSE

All bulk and block deals →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.00)

Weaknesses

  • Low Return on Equity (4.6%)
  • Thin net profit margin (-11.4%)
  • Tight liquidity (Current Ratio 0.68)

Opportunities

Data unavailable.

Threats

  • PE above 35 (37.2) -- priced for continued strong execution
  • Down 55.7% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Bacil Pharma Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.